Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685242 · ClinicalTrials.gov registry record · Phase 3
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
A Phase 3 study, sponsored by Aciex Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT01685242 is a Phase 3 study that has completed, run by Aciex Therapeutics. The registered enrollment target is 100 participants.
The verdict
NCT01685242, a Phase 3 study, has completed, sponsored by Aciex Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
Interventions
- DRUG AC-170 0.24%
- DRUG AC-170 0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01685242
The ClinicalTrials.gov registry entry for NCT01685242 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aciex Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AC-170 0.24% is the first listed.
NCT01685242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01685242 about?
NCT01685242 is a clinical study titled "A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle". The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
What is the current status of trial NCT01685242?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2012-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01685242?
The interventions under investigation include: AC-170 0.24% (DRUG), AC-170 0% (DRUG).
Who is sponsoring clinical trial NCT01685242?
This trial is sponsored by Aciex Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.